Abeona Therapeutics

The revenue model is inherently lumpy early on: each patient represents multi‑million‑dollar net revenue, with timing governed by biopsy slots, individualized manufacturing, sterility release, operating room scheduling and insurance logistics. 2025 showed this sensitivity when an FDA‑mandated rapid sterility assay initially yielded a false positive that delayed the first treatments to Q4 2025; cadence resumed in early 2026 with multiple biopsies and ongoing runs.

Management targets scaling to roughly 10 patients per month by mid‑2026, but variability in referral‑to‑treatment cycle time and manufacturing yields remains a risk. Long‑term visibility improves once throughput stabilizes and QTCs mature, yet competitive dynamics (Vyjuvek) and tiny TAM keep forecast error high.